Goldberg MS, Siegel JJ, Ahmed K, Kurley SJ, Farberg AS. A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC). J of Skin [Internet]. 2022Nov.16 [cited 2024Sep.20];6(6):s95. Available from: https://dermsquared.com/skin/article/view/1854